Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

navtemadlin (KRT-232)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Amgen, Kartos Therap

Drug class:

MDM2 inhibitor

Related drugs:

TP53 wild-type	Solid Tumor	TP53 wild-type	Solid Tumor	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2	KRT-232 Sensitive: C2 – Inclusion Criteria KRT-232 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	dabrafenib + KRT-232 Sensitive: C3 – Early Trials dabrafenib + KRT-232 Sensitive : C3	dabrafenib + KRT-232 Sensitive: C3 – Early Trials dabrafenib + KRT-232 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	trametinib + KRT-232 Sensitive: C3 – Early Trials trametinib + KRT-232 Sensitive : C3	trametinib + KRT-232 Sensitive: C3 – Early Trials trametinib + KRT-232 Sensitive : C3
TP53 wild-type	Multiple Myeloma	TP53 wild-type	Multiple Myeloma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
TP53 wild-type	Melanoma	TP53 wild-type	Melanoma	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3	trametinib + dabrafenib + KRT-232 Sensitive: C3 – Early Trials trametinib + dabrafenib + KRT-232 Sensitive : C3
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3
TP53 wild-type	Chronic Lymphocytic Leukemia	TP53 wild-type	Chronic Lymphocytic Leukemia	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3	acalabrutinib + KRT-232 Sensitive: C3 – Early Trials acalabrutinib + KRT-232 Sensitive : C3
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	trametinib + KRT-232 Sensitive: D – Preclinical trametinib + KRT-232 Sensitive : D	trametinib + KRT-232 Sensitive: D – Preclinical trametinib + KRT-232 Sensitive : D
BRAF V600M	Melanoma	BRAF V600M	Melanoma	KRT-232 Sensitive: D – Preclinical KRT-232 Sensitive : D	KRT-232 Sensitive: D – Preclinical KRT-232 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	KRT-232 Sensitive: D – Preclinical KRT-232 Sensitive : D	KRT-232 Sensitive: D – Preclinical KRT-232 Sensitive : D
TP53 wild-type	Breast Cancer	TP53 wild-type	Breast Cancer	KRT-232 + APG-115 Sensitive: D – Preclinical KRT-232 + APG-115 Sensitive : D	KRT-232 + APG-115 Sensitive: D – Preclinical KRT-232 + APG-115 Sensitive : D
NRAS mutation	Thyroid Gland Carcinoma	NRAS mutation	Thyroid Gland Carcinoma	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D
BRAF mutation	Thyroid Gland Carcinoma	BRAF mutation	Thyroid Gland Carcinoma	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D
KRAS mutation	Thyroid Gland Carcinoma	KRAS mutation	Thyroid Gland Carcinoma	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D	selumetinib + KRT-232 Sensitive: D – Preclinical selumetinib + KRT-232 Sensitive : D